Contents
Academic literature on the topic 'Glucosamine - Therapeutic use'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glucosamine - Therapeutic use.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Glucosamine - Therapeutic use"
1
Machado, Eduardo, Patricia Machado, and Paulo Afonso Cunali. "Use of chondroitin sulphate and glucosamine sulphate in degenerative changes in TMJ: a systematic review." Dental Press Journal of Orthodontics 17, no. 4 (August 2012): e1-e5. http://dx.doi.org/10.1590/s2176-94512012000400006.
Full textAbstract:
INTRODUCTION: Degenerative changes in Temporomandibular Joint (TMJ) have increased in prevalence and severity over the years. Within this context, it's necessary to obtain safe and effective therapies for control and management of the patient in cases of osteoarthritis and osteoarthrosis of the TMJ. Therapeutic options range from intra-articular infiltration protocols, occlusal splints, pharmacological therapies and physiotherapy and educational measures. The alternative treatment with structure-modifying agents, like as chondroitin and glucosamine sulphates, showed promising results, and especially safety. Thus, through a systematic literature review, this study aimed to analyze and discuss effectiveness and safety of chondroitin and glucosamine in degenerative changes of the TMJ. METHODS: Survey in research bases MEDLINE, Cochrane, EMBASE, Pubmed, Lilacs and BBO, between the years of 1966 and January 2009, with focus in randomized clinical trial (RCTs) and quasi-randomized clinical trials, systematic reviews and meta-analysis. RESULTS: After application of the inclusion criteria 2 articles were selected, both randomized controlled double-blind clinical trials, which evaluated the effectiveness of chondroitin and glucosamine in degenerative changes of the TMJ. CONCLUSIONS: There is the necessity of further RCT, with representative samples and long follow-up time, to obtainment more precise cause-effect relationships and to achieve an effective and objective protocol involving chondroitin and glucosamine in cases of degenerative changes of the TMJ.
2
Hsu, Chia-Hao, Nin-Chieh Hsu, Chia-Lung Shih, Hsuan-Ti Huang, Chung-Hwan Chen, and Pei-Hsi Chou. "Medication-Taking Habit and Outcome of Glucosamine Sulfate for Osteoarthritis Patients Influenced by National Health Insurance Regulations in Taiwan." Journal of Clinical Medicine 8, no. 10 (October 19, 2019): 1734. http://dx.doi.org/10.3390/jcm8101734.
Full textAbstract:
This study compared the dosage and different medication-taking habits of glucosamine sulfate (GS) for osteoarthritis patients and evaluated the influence of the National Health Insurance (NHI) prescription guidelines. The subjects were collected from the Taiwan NHI Research Database from 1 January 2004, to 31 December 2008, and 10,501 osteoarthritis patients were included. Then, 271 patients who continuously used nonsteroidal anti-inflammatory drug (NSAIDs) and started to receive glucosamine for the first time since 2005 (no glucosamine use in 2004) were compared with 593 age-matched patients who continuously used NSAIDs but never received any glucosamine drugs from 2004 to 2008. The mean treatment duration of the glucosamine-treated and NSAID-treated groups was 40.38 ± 7.89 and 45.82 ± 3.89 months, respectively. The most common medication-taking habit was 250 mg 3 times a day for 3 months and discontinued for 3 months. It was as indicated and covered by the NHI. Only 0.7% of patients used the recommended daily dosage of 1500 mg. Patients using GS surprisingly had a higher incidence rate of joint replacement surgery than those who did not use GS. The NHI prescription guidelines may cause patient selection bias, which decreases the efficacy of GS. Moreover, patients tend to have an altered medication-taking habit, with a daily dosage of 750 mg, which is lower than the recommended therapeutic dose.
3
da Camara, Carlos C., and Gregory V. Dowless. "Glucosamine Sulfate for Osteoarthritis." Annals of Pharmacotherapy 32, no. 5 (May 1998): 580–87. http://dx.doi.org/10.1345/aph.17214.
Full textAbstract:
OBJECTIVE: To characterize the usefulness of glucosamine sulfate in the treatment of patients with osteoarthritis (OA). DATA SOURCES AND STUDY SELECTION: Pertinent citations were identified via a MEDLINE search (January 1975–March 1997). Only trials available in the English language involving human subjects, OA, and glucosamine sulfate were selected for review. DATA SYNTHESIS: OA is the most common form of arthritis and represents a major cause of morbidity and disability in the elderly. The main symptom of OA is pain and most of the commonly prescribed medications (e.g, acetaminophen, nonsteroidal antiinflammatory drugs) have been targeted at relieving the pain. Some of these medications have serious adverse effects and do not necessarily change the natural course of the disease. Glucosamine sulfate, a nutritional supplement, has recently emerged as an alternative treatment option for patients with OA. The beneficial effects of this chondroprotective agent have been reported to reverse or at least stop the progression of the disease without inducing serious adverse effects. Limited data from short-term human trials suggest that glucosamine sulfate administered orally, intravenously, intramuscularly, and intraarticularly may produce a gradual and progressive reduction in joint pain and tenderness, as well as improved range of motion and walking speed. Results of the trials have also shown that glucosamine has produced consistent benefits (>50% overall improvement in symptom scores) in patients with OA and that, in some cases, it may be equal or superior to ibuprofen in controlling symptoms. CONCLUSIONS: There is evidence that glucosamine sulfate may provide pain relief, reduce tenderness, and improve mobility in patients with OA. Most of the current data, however, are derived from the European and Asian literature and there are no studies supporting the use of this agent in the US. The studies published to date have been done in small numbers of patients; adequate long-term trials examining the safety, efficacy, and optimal dosage requirements of glucosamine sulfate are lacking. Most of the available clinical data are difficult to interpret due to serious deficiencies in study design. Furthermore, studies evaluating the appropriate place of glucosamine sulfate in the therapeutic armamentarium of OA remain to be done.
4
Salazar, Juan, Luis Bello, Mervin Chávez, Roberto Añez, Joselyn Rojas, and Valmore Bermúdez. "Glucosamine for Osteoarthritis: Biological Effects, Clinical Efficacy, and Safety on Glucose Metabolism." Arthritis 2014 (February 11, 2014): 1–13. http://dx.doi.org/10.1155/2014/432463.
Full textAbstract:
Osteoarthritis is a chronic degenerative disorder that currently represents one of the main causes of disability within the elderly population and an important presenting complaint overall. The pathophysiologic basis of osteoarthritis entails a complex group of interactions among biochemical and mechanical factors that have been better characterized in light of a recent spike in research on the subject. This has led to an ongoing search for ideal therapeutic management schemes for these patients, where glucosamine is one of the most frequently used alternatives worldwide due to their chondroprotective properties and their long-term effects. Its use in the treatment of osteoarthritis is well established; yet despite being considered effective by many research groups, controversy surrounds their true effectiveness. This situation stems from several methodological aspects which hinder appropriate data analysis and comparison in this context, particularly regarding objectives and target variables. Similar difficulties surround the assessment of the potential ability of glucosamine formulations to alter glucose metabolism. Nevertheless, evidence supporting diabetogenesis by glucosamine remains scarce in humans, and to date, this association should be considered only a theoretical possibility.
5
Morozenko, D. V., and E. V. Glebova. "КЛІНІЧНА ЕФЕКТИВНІСТЬ ПРЕПАРАТУ, ЩО МІСТИТЬ ГЛЮКОЗАМІНУ ГІДРОХЛОРИД, У ЛІКУВАННІ СЕЧОКАМ’ЯНОЇ ХВОРОБИ ДОМАШНІХ КОТІВ." Scientific Messenger of LNU of Veterinary Medicine and Biotechnology 18, no. 3(70) (September 14, 2016): 184–87. http://dx.doi.org/10.15421/nvlvet7044.
Full textAbstract:
In the article the question of the effectiveness of treatment of domestic cats with urolithiasis which a preparation containing glucosamine hydrochloride was used in the scheme of therapeutic interventions (Uri–Easy). According to the research, it was found that the treatment regimen with the use of drug Uri–Easy containing glucosamine hydrochloride, promotes more rapid clinical recovery of the animals, as well as the dissolution of crystals of calcium tripelfosfat glycosaminoglycans and increasing concentration in urine. This is confirmed by the fact that the 14 day treatment the animals in the second group with glucosamine hydrochloride concentration glycosaminoglycan in urine was lower by 12.3% than that in healthy cats with only single crystals of calcium tripelfosfat encountered in urine sediment. In the first group of glycosaminoglycans content in urine on day 14 were 62.6% lower than the clinically healthy cats, the precipitate thus maintained a moderate amount of calcium tripelfosfat crystals. In this second group of glycosaminoglycan concentration on the 14th day it was closer to normal, and only a few crystals were observed in urine. Thus, we can say that the introduction to the treatment regimen of the drug containing glucosamine hydrochloride, to accelerate healing cats with urolithiasis, which is confirmed by laboratory tests. This allows us to recommend the drug Uri–Easy for the comprehensive treatment of domestic cats suffering from struvite urolithiasis.
6
Blanco, Francisco J., María Camacho-Encina, Lucía González-Rodríguez, Ignacio Rego-Pérez, Jesús Mateos, Patricia Fernández-Puente, Lucía Lourido, et al. "Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis." Therapeutic Advances in Chronic Disease 10 (January 2019): 204062231987001. http://dx.doi.org/10.1177/2040622319870013.
Full textAbstract:
Background: In the present study, we explored potential protein biomarkers useful to predict the therapeutic response of knee osteoarthritis (KOA) patients treated with pharmaceutical grade Chondroitin sulfate/Glucosamine hydrochloride (CS+GH; Droglican, Bioiberica), in order to optimize therapeutic outcomes. Methods: A shotgun proteomic analysis by iTRAQ labelling and liquid chromatography–mass spectrometry (LC-MS/MS) was performed using sera from 40 patients enrolled in the Multicentre Osteoarthritis interVEntion trial with Sysadoa (MOVES). The panel of proteins potentially useful to predict KOA patient’s response was clinically validated in the whole MOVES cohort at baseline ( n = 506) using commercially available enzyme-linked immunosorbent assays kits. Logistic regression models and receiver-operating-characteristics (ROC) curves were used to analyze the contribution of these proteins to our prediction models of symptomatic drug response in KOA. Results: In the discovery phase of the study, a panel of six putative predictive biomarkers of response to CS+GH (APOA2, APOA4, APOH, ITIH1, C4BPa and ORM2) were identified by shotgun proteomics. Data are available via ProteomeXchange with identifier PXD012444. In the verification phase, the panel was verified in a larger set of KOA patients ( n = 262). Finally, ITIH1 and ORM2 were qualified by a blind test in the whole MOVES cohort at baseline. The combination of these biomarkers with clinical variables predict the patients’ response to CS+GH with a specificity of 79.5% and a sensitivity of 77.1%. Conclusions: Combining clinical and analytical parameters, we identified one biomarker that could accurately predict KOA patients’ response to CS+GH treatment. Its use would allow an increase in response rates and safety for the patients suffering KOA.
7
Djunaedi, Mochamad, and Syed Azhar Syed Sulaiman. "THE PHARMACIST’S ASSESSMENT ON PATIENTS WHO CONSUME SUPPLEMENTS AND HERBAL WHILE UNDERGOING WARFARIN THERAPY." Asian Journal of Pharmaceutical and Clinical Research 11, no. 13 (April 26, 2018): 49. http://dx.doi.org/10.22159/ajpcr.2018.v11s1.26566.
Full textAbstract:
Objective: The supplements and herbal medicines used should be monitored in a patient taking warfarin, to achieve the goal of warfarin anticoagulation. This study aims to evaluate the impacts of the supplement and the herbs used on the performance of anticoagulation.Methods: There were 214 eligible patients for having CHADS2 score >2 registered at warfarin-medication therapy adherence clinic coordinated by Cardiac Hospitals in Malaysia in 2012 included for this study. They have been assessed using a trained pharmacist regarding the safety and efficacy of warfarin as per guideline. Results: Supplements and herbs are commonly used by the patient (61.2%) who is taking warfarin. Some patients (23%) have decided not to use or stop using it after being consulted by the pharmacist. Some are even starting to use it (37%). Effects of supplements and herbal medicines were found to decrease in the International normalized ratio (INR) reading as 33%, increasing in 37% the INR reading. Further, pharmacist action is to do a dose adjustment to reach INR in the therapeutic range 2.0–3.0. Supplements consumed as categorized as phytomedicine-containing herbs, such as Omega3 and glucosamine. Whereas herbs used as beetle leaves and the product of extracted herbs, for example, Gingko biloba, Cordyceps, etc. Conclusion: Monitoring by pharmacist is needed to achieve the goal of warfarin as well as to minimize the INR out of therapeutic. The use of herbal and supplement is found to be a factor contributes to the performance of anticoagulation control which has been successfully achieved 71.2%.
8
Lippiello, Louis. "Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate." Evidence-Based Complementary and Alternative Medicine 4, no. 2 (2007): 219–24. http://dx.doi.org/10.1093/ecam/nel081.
Full textAbstract:
Clinical testing of the nutraceuticals glucosamine (glcN) and chondroitin sulfate (CS) has shown efficacy in providing relief from symptoms in osteoarthritic patients.In vitroandin vivostudies support existence of a synergistic relationship upregulating synthetic activity in chondrocytes. A combination of glcN and CS may also be useful as adjunct therapy in sports-related injuries if similar upregulation of collagen synthesis is elicited in accessory ligament and tendon joint tissue. Collagen and non-collagenous protein (NCP) synthesis in cultures of bovine tenocytes, ligament cells and chondrocytes exposed to glcN + CS were assayed by uptake of radiolabeled proline into collagenase-sensitive material. Assay of radiolabel in hydroxyproline (a specific marker for collagen synthesis) following HPLC isolation confirmed the specificity of the metabolic effect. Synthesis of total collagenase-sensitive material was maximally upregulated at physiologically obtainable doses of glcN + CS. Tissue response followed the sequence ligament cells (+69%) > chondrocytes (+56%) > tenocytes (+22%). Labeled hydroxyproline increased by 132% in ligament cells, 27% in tenocytes and 49% in epitendon cells after a 48 h exposure to 5 μg ml−1glcN + 4 μg ml−1CS. Low dose combinations of glcN and CS effectively stimulatein vitrocollagen and NCP synthesis by ligament cells, tenocytes and chondrocytes. Hence, therapeutic use following accessory joint tissue trauma may help augment repair processes.
9
Dydykina, I. S., E. V. Arutyunova, P. S. Kovalenko, and E. G. Zotkin. "The clinical significance of and prospects for the use of biopolymer-based microheterogeneous collagen-containing injectable hydrogel in the therapy of osteoarthritis." Modern Rheumatology Journal 14, no. 4 (November 25, 2020): 132–37. http://dx.doi.org/10.14412/1996-7012-2020-4-132-137.
Full textAbstract:
The paper gives the current definition of osteoarthritis (OA), which reflects the pathogenetic and clinical characteristics of this disease, as well as general principles for choosing an OA treatment. It describes the effect of glucosamine and chondroitin on the key pathogenetic mechanisms of OA. It is noted that one of the promising areas of therapy for OA is the intra-articular administration of biopolymer-based hydrogels that provide not only an anti-inflammatory, but also regenerative effect that has been experimentally confirmed during their injection into the tendon sheaths. There are data on the efficacy and safety of the Russian drug Sphero®gel, a biopolymer-based microheterogeneous collagen-containing hydrogel that belongs to a class of multicomponent biopolymer-based extracellular matrix mimetics. It consists of the cross-linked farm animal tissue-derived collagen microparticles placed in the gel base. The gel is not only a structural base for collagen microparticles; it also has its own therapeutic potential, since it is structurally similar to the natural extracellular matrix. The drug contains collagen, biologically active components of the extracellular matrix, such as proteoglycans, glycoproteins, uronic acids, growth factors, monosaccharides, and chondroitin sulfate. Extended-release symptomatic agents, Sphero®gel among them, are currently recommended for the treatment of OA. Application of Sphero®gel contributes to increased joint mobility and reduced pain, which allows the limited use of nonsteroidal anti-inflammatory drugs that cause adverse reactions, especially in the presence of comorbid diseases.
10
Kanneppady, Sowmya Sham, Sham Kishor Kanneppady, Vijaya Raghavan, Aung Myo Oo, and Ohn Mar Lwin. "Prescription Pattern of Primary Osteoarthritis in Tertiary Medical Centre." Journal of Health and Allied Sciences NU 07, no. 04 (December 2017): 037–42. http://dx.doi.org/10.1055/s-0040-1708734.
Full textAbstract:
Abstract Objectives: Osteoarthritis (OA) is one of the commonest joint/musculoskeletal disorders, affecting the middle aged and elderly, although younger people may be affected as a result of injury or overuse. The study aimed to analyze the data, evaluate the prescription pattern and rationality of the use of drugs in the treatment of primary OA with due emphasis on the available treatment regimens. Materials and methods: Medical case records of patients suffering from primary OA attending the department of Orthopedics of a tertiary medical centre were the source of data. The study was carried out prospectively for a period of 20 months (from December 2012 to July 2014). Results: 296 case records were collected in which the total number of drugs prescribed were 550. OA was more common in females (51.7%) and was more prevalent in the age group of 30–40 years (39%). Out of 550 drugs prescribed, Aceclofenac was the most frequently prescribed NSAID (29%) followed by Diclofenac (23%). Nimesulide and Paracetamol was the most commonly prescribed fixed dose combination (53). Among gastroprotectives, Ranitidine figured in 66 prescriptions. Glucocorticoids were prescribed orally and intraarticularly in 17 and 14 cases respectively. Dietary supplements like Calcium+Vitamin D (42) and Glucosamine Sulfate + Chondroitin Sulfate complex (19) were also prescribed. Conclusion: The above study highlights the rational use of therapeutic agents for primary OA.
Dissertations / Theses on the topic "Glucosamine - Therapeutic use"
1
Levy, Romy. "The effect of OsteoEze Gold™ on the inflammatory marker CRP and quality of life in osteoarthritis of the knee." Thesis, 2014. http://hdl.handle.net/10210/12382.
Full textAbstract:
M.Tech. (Homoeopathy)Osteoarthritis (OA) is a chronic and debilitating condition, characterized by irreversible damage to the joint space, most commonly affecting the knees, hips, hands and spine (Colledge et al., 2010). OA is the leading cause of joint pain and disability in middle-aged and elderly persons (Long et al., 2001). The prevalence of OA of the knee in adults living in the United Sates has grown from a reported 21 million in 1990 to a total estimate of 26.9 million in 2005 (CDC, 2011). By the age of 65 years, 80% of the total population has been reported as showing radiographic evidence of OA; while a 20-30% of the total population is symptomatic with radiographic evidence of OA (Doherty et al., 2006). Conventional treatment for OA of the knee is aimed at pain management by use of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). Some negative effects of these drugs include drug dependency, liver and kidney damage, cardiovascular pathologies, gastric upset and depression. Corticosteroid injections are also used to alleviate chronic inflammation and joint pain, but may lead to further joint destruction (Shamoon and Hochberg, 2000; Mayo Foundation for Medical Education and Research, 2011). OsteoEze Gold™ is a nutraceutical product that contains chondroitin sulphate, glucosamine sulphate, vitamin C and manganese. In combination, the constituents of OsteoEze Gold™ have been shown to be useful in the treatment for OA of the knee (Clegg et al., 2006). In addition, studies have shown that these ingredients prove effective in reducing moderate to severe pain in sufferers of OA of the knee (Vidyasagar et al., 2004). The aim of this study was to determine the effect of OsteoEze Gold™ on the inflammatory marker C-reactive protein (CRP) and quality of life in OA of the knee using blood tests and the Arthritic Impact Measurement Scales (AIMS2SF) respectively. This was a 16-week, double blind, placebo-controlled study using matched pairs according to age, gender and severity of symptoms, and formed part of a group study, with another researcher, who utilized the Intermittent and Constant Osteoarthritis Pain scale (ICOAP) Short Physical Performance Battery (SPPB) and the same sample...
2
Macquilkan, Kim Elizabeth. "The effect of OsteoEze Gold™ on pain and functional ability in osteoarthritis of the knee." Thesis, 2014. http://hdl.handle.net/10210/11139.
Full textAbstract:
M.Tech. (Homoeopathy)Osteoarthritis (OA) is a musculoskeletal condition affecting the synovial joints of the body, most commonly the knee and hip (Colledge et al., 2010). OA is the most prevalent joint disorder worldwide (Ickinger & Tikly, 2010). The prevalence of OA of the knee in developing countries, including South Africa, is expected to increase due to the increase in obesity and life-expectancy (Woolf & Pfleger, 2003). OA not only impacts negatively on many areas of the patient’s personal life, but it also has a considerable impact on health care systems and cost to the patient (Lapsley et al., 2001; Majani et al., 2005). The two main complaints in patients suffering from OA of the knee are knee pain and decreased daily functionality, such as walking (Samson et al., 2007). The main aim of conventional treatment is pain reduction. This treatment does not prevent progression of the OA, and may have negative side-effects (Day & Graham, 2005). Treatments for OA, such as OsteoEze GoldTM, may provide an effective and safer alternative. The aim of this study is to determine the effect of OsteoEze GoldTM on pain and functional ability in osteoarthritis of the knee using the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale: knee version (Appendix D) and the Short Physical Performance Battery (SPPB) test (Appendix E). This was a 16-week study, conducted at the Homoeopathic Health Centre, Doornfontein campus (DFC), University of Johannesburg (UJ). The study was randomised, double blind placebo controlled, and matched pairs were utilised. Sixty-seven participants, who satisfied the inclusion and exclusion criteria, were recruited, and 48 of the participants completed the study. Participants were recruited by advertisements, placed in and around the UJ Homoeopathy Health Centre (with relevant permission given) and by word of mouth. The participants were split into two groups using matched pairs according to age, gender and severity of symptoms (Appendix H). The participants in group A received the OsteoEze GoldTM capsules, and the participants in group B received the placebo capsules. Each capsule of OsteoEze GoldTM contained 500mg glucosamine sulphate, 267mg of chondroitin sulphate, 50mg of vitamin C and 1mg of manganese. The OsteoEze GoldTM or the placebo capsules were distributed at the initial (week-0) and second (week-8) consultations.
3
Penque, Brent A. "Mechanisms of hexosamine-induced cholesterol accumulation and therapeutic actions of chromium." Thesis, 2014. http://hdl.handle.net/1805/3805.
Full textAbstract:
Indiana University-Purdue University Indianapolis (IUPUI)Excess caloric intake and/or obesity currently remain the largest predisposing risk factors for the development of type 2 diabetes. Discerning the cellular and molecular mechanisms responsible and amendable to therapy represents a growing challenge in medicine. At a cellular level, increased activity of the hexosamine biosynthesis pathway (HBP), a sensor of excess energy status, has been suggested to promote the exacerbation of insulin resistance through increasing adipose tissue and skeletal muscle membrane cholesterol content. This in turn compromises cortical filamentous actin structure necessary for proper incorporation of the insulin-sensitive glucose transporter GLUT4 into the plasma membrane. The current studies attempted to elucidate the mechanism by which hexosamines provoke membrane cholesterol toxicity and insulin resistance. In 3T3-L1 adipocytes cultured with pathophysiologic hyperinsulinemia to induce insulin resistance, increased HBP flux was observed. This occurred concomitant with gains in the mRNA and protein levels of HMG-CoA reductase (HMGR), the rate limiting enzyme in cholesterol synthesis. Mechanistically, immunoprecipitation demonstrated increased HBP-induced N-acetylglucosamine (O-GlcNAc) modification of specificity protein 1 (Sp1), a regulator of HMGR synthesis. This was associated with increased affinity toward and activity of Hmgcr, the gene encoding HMGR. Global HBP inhibition or Sp1 binding to DNA prevented membrane cholesterol accrual, filamentous actin loss, and glucose transport dysfunction. Furthermore, hyperinsulinemia and HBP activation impaired cholesterol efflux in adipocytes, exacerbating cholesterol toxicity and potentially contributing to cardiovascular disease. In this regard, chromium picolinate (CrPic), known to have beneficial effects on glucose and lipoprotein metabolism, improved cholesterol efflux and restored membrane cholesterol content. To test the role of membrane cholesterol accumulation in vivo, studies were conducted on C57Bl/6J mice fed a low or high fat diet. High fat feeding promoted increased HBP activity, membrane cholesterol accumulation, and insulin resistance. Supplementation of mice with CrPic in their drinking water (8µg/kg/day) countered these derangements and improved insulin sensitivity. Together, these data provide mechanistic insight for the role of membrane cholesterol stress in the development of insulin resistance, as well as cardiovascular disease, and highlight a novel therapeutic action of chromium entailing inhibition of the HBP pathway.
Books on the topic "Glucosamine - Therapeutic use"
1
Basic Health Publications User's guide to glucosamine & chondroitin. North Bergen, NJ: Basic Health Publications, Inc., 2002.
Find full text
2
Brenda, Adderly, and Fox Barry, eds. Maximizing the arthritis cure: A step-by-step program to faster, stronger healing during any stage of the cure. New York: St. Martin's Press, 1998.
Find full text
3
Theodosakis, Jason. Maximizing the arthritis cure: A step-by-step program to faster, stronger healing during any stage of the cure. London: Century, 1998.
Find full text
4
Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. New York: St. Martin's Griffin, 1998.
Find full text
5
Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. New York: St. Martin's Press, 1997.
Find full text
6
Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical breakthrough that can halt, reverse, and even cure osteoarthritis. London: Century, 1997.
Find full text
7
Brenda, Adderly, and Fox Barry, eds. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. New York: St. Martin's Paperbacks, 1997.
Find full text
9
Theodosakis, Jason. The arthritis cure: The medical miracle that can halt, reverse, and may even cure osteoarthritis. New York: St. Martin's Press, 2004.
Find full text
10
Brenda, Adderly, and Fox Barry, eds. Guan jie yen liao fa: The Arthritis cure. Taibei Shi: Di teng chu ban tu shu yu xian gong si, 1998.
Find full text